title: Amelioration of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma.
abstract: Vasoactive intestinal polypeptide secreting islet cell tumors (VIPomas) are neuroendocrine tumors that secrete excessive amounts of vasoactive intestinal polypeptide (VIP) that cause distinct syndromes characterized by large-volume diarrhea, hypokalemia, and dehydration. The annual incidence of these tumors is estimated to be about one per 10,000,000 individuals in the general population. We report a successful treatment of VIPoma with hepatic chemoembolization of a metastatic hepatic lesion evidenced by a reduction of VIP levels and resolutions of symptoms in a patient with pancreatic VIPoma unresponsive to increased doses of an octreotide analog.
authors.affiliation: Hospital of Saint Raphael, New Haven, Connecticut, USA.
authors.forename: Walid
authors.initials: W
authors.lastname: Shaib
authors.forename: Kisha
authors.initials: K
authors.lastname: Mitchell
authors.forename: M Wasif
authors.initials: MW
authors.lastname: Saif
mesh_terms: D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D004621:Embolization, Therapeutic; D005260:Female; D006499:Hepatic Artery / Q000473:pathology / Q000601:surgery*; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D016896:Treatment Outcome; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism*; D003969:Vipoma / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery
chemical_list: D018931:Antineoplastic Agents, Hormonal; D014660:Vasoactive Intestinal Peptide; D015282:Octreotide